Although patients with anti-LGI-1 and CASPR2 antibodies have clinical heterogeneity, they also exhibit significant overlapping clinical symptomatology; the antibodies to LGI1 are most commonly associated with limbic encephalitis and epilepsy while the antibodies to CASPR2 with Morvan syndrome, neuromyotonia, and neuropathic pain [1, 5, 8, 9, 25]. This evidence concerns the gene LGI1 and epilepsy.